Agilent Technologies Diagnostics and Genomics — Net revenue increased by 14.8% to $442.00M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 24.2%, from $356.00M to $442.00M. Over 3 years (FY 2021 to FY 2024), Diagnostics and Genomics — Net revenue shows an upward trend with a 8.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests strong market adoption and competitive positioning of the segment's diagnostic and genomic technologies.
This represents the total gross sales generated by the diagnostics and genomics segment after deducting returns, allowan...
Standard revenue reporting across all life science and diagnostic equipment manufacturers.
a_segment_diagnostics_and_genomics_net_revenue| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $315.00M | $346.00M | $341.00M | $339.00M | $358.00M | $340.00M | $352.00M | $342.00M | $362.00M | $349.00M | $356.00M | $407.00M | $417.00M | $385.00M | $442.00M |
| QoQ Change | — | +9.8% | -1.4% | -0.6% | +5.6% | -5.0% | +3.5% | -2.8% | +5.8% | -3.6% | +2.0% | +14.3% | +2.5% | -7.7% | +14.8% |
| YoY Change | — | — | — | — | +13.7% | -1.7% | +3.2% | +0.9% | +1.1% | +2.6% | +1.1% | +19.0% | +15.2% | +10.3% | +24.2% |